News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
122,509 Results
Type
Article (6090)
Company Profile (24)
Press Release (116395)
Section
Business (35809)
Career Advice (161)
Deals (5954)
Drug Delivery (11)
Drug Development (6583)
Employer Resources (20)
FDA (3560)
Job Trends (2535)
News (53082)
Policy (4572)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (1)
2024 BioMidwest Digital (3)
2024 Bio NC Digital (1)
2024 Biotech Bay Standard (2)
2024 Biotech Beach Standard (1)
2024 Genetown Standard (2)
2024 Lone Star Bio Digital (1)
Academia (490)
Accelerated approval (1)
Adcomms (1)
Allergies (11)
Alliances (12188)
ALS (8)
Alzheimer's disease (333)
Antibody-drug conjugate (ADC) (7)
Approvals (3568)
Artificial intelligence (98)
Autoimmune disease (3)
Automation (4)
Bankruptcy (55)
Best Places to Work (2091)
BIOSECURE Act (2)
Biosimilars (7)
Biotechnology (16)
Bladder cancer (11)
Brain cancer (7)
Breast cancer (70)
Cancer (478)
Cardiovascular disease (33)
Career advice (144)
Career pathing (1)
CAR-T (13)
Cell therapy (44)
Cervical cancer (7)
Clinical research (5037)
Collaboration (193)
Compensation (23)
Complete response letters (1)
COVID-19 (538)
CRISPR (3)
C-suite (44)
Cystic fibrosis (9)
Data (301)
Decentralized trials (1)
Denatured (3)
Depression (6)
Diabetes (20)
Diagnostics (5861)
Digital health (7)
Diversity (4)
Diversity, equity & inclusion (5)
Drug discovery (17)
Drug pricing (12)
Drug shortages (1)
Duchenne muscular dystrophy (7)
Earnings (11391)
Editorial (5)
Employer branding (5)
Employer resources (20)
Events (15426)
Executive appointments (131)
FDA (3775)
Featured Employer (5)
Fibrodysplasia Ossificans Progressiva (1)
Funding (155)
Gene editing (14)
Generative AI (10)
Gene therapy (49)
GLP-1 (65)
Government (817)
Grass and pollen (1)
Guidances (10)
Healthcare (3552)
IgA nephropathy (1)
Immunology and inflammation (10)
Indications (3)
Infectious disease (573)
Inflammatory bowel disease (13)
Inflation Reduction Act (2)
Influenza (15)
Intellectual property (8)
Interviews (21)
IPO (2134)
IRA (3)
Job creations (492)
Job search strategy (134)
Kidney cancer (5)
Labor market (1)
Layoffs (32)
Leadership (1)
Legal (671)
Liver cancer (13)
Lung cancer (50)
Lymphoma (36)
Machine learning (3)
Management (4)
Manufacturing (53)
MASH (7)
Medical device (2802)
Medtech (2804)
Mergers & acquisitions (3935)
Metabolic disorders (45)
Multiple sclerosis (20)
NASH (3)
Neurodegenerative disease (16)
Neuropsychiatric disorders (2)
Neuroscience (403)
NextGen: Class of 2025 (1036)
Non-profit (796)
Northern California (452)
Now hiring (3)
Obesity (16)
Opinion (33)
Ovarian cancer (15)
Pain (5)
Pancreatic cancer (12)
Parkinson's disease (17)
Partnered (4)
Patents (26)
Patient recruitment (11)
Peanut (5)
People (10422)
Pharmaceutical (1)
Pharmacy benefit managers (2)
Phase I (1654)
Phase II (2124)
Phase III (1913)
Pipeline (169)
Policy (9)
Postmarket research (235)
Preclinical (733)
Press Release (12)
Prostate cancer (39)
Psychedelics (1)
Radiopharmaceuticals (121)
Rare diseases (58)
Real estate (999)
Recruiting (10)
Regulatory (3433)
Reports (10)
Research institute (513)
Resumes & cover letters (20)
Rett syndrome (1)
RSV (2)
Schizophrenia (3)
Series A (19)
Series B (19)
Service/supplier (2)
Sickle cell disease (16)
Southern California (320)
Special edition (1)
Spinal muscular atrophy (13)
Sponsored (7)
Startups (753)
Stomach cancer (3)
Supply chain (8)
Tariffs (1)
The Weekly (10)
United States (3621)
Vaccines (65)
Venture capitalists (7)
Weight loss (8)
Women's health (8)
Worklife (1)
Date
Today (24)
Last 7 days (128)
Last 30 days (436)
Last 365 days (5471)
2025 (1867)
2024 (5801)
2023 (6925)
2022 (11190)
2021 (10711)
2020 (10266)
2019 (7983)
2018 (6092)
2017 (6137)
2016 (6149)
2015 (6946)
2014 (5188)
2013 (4567)
2012 (4855)
2011 (5104)
2010 (4406)
Location
Africa (151)
Alabama (7)
Alaska (2)
Arizona (60)
Arkansas (2)
Asia (6004)
Australia (1501)
California (939)
Canada (283)
China (36)
Colorado (58)
Connecticut (63)
Delaware (7)
Europe (16936)
Florida (118)
Georgia (48)
Idaho (7)
Illinois (121)
India (5)
Indiana (35)
Iowa (4)
Japan (24)
Kansas (13)
Kentucky (4)
Louisiana (2)
Maine (21)
Maryland (115)
Massachusetts (503)
Michigan (69)
Minnesota (96)
Missouri (30)
Montana (4)
Nebraska (10)
Nevada (1)
New Hampshire (19)
New Jersey (171)
New Mexico (17)
New York (349)
North Carolina (190)
North Dakota (6)
Northern California (452)
Ohio (36)
Oklahoma (2)
Oregon (7)
Pennsylvania (108)
Rhode Island (5)
South America (202)
South Carolina (4)
Southern California (320)
Tennessee (37)
Texas (197)
Utah (94)
Virginia (39)
Washington D.C. (7)
Washington State (80)
Wisconsin (31)
122,509 Results for "blue earth diagnostics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Blue Earth Diagnostics Highlights Presentations on POSLUMA®
Blue Earth Diagnostics Highlights Presentations on POSLUMA® at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting to be held June 8 to 11, 2024, in Toronto, Canada.
May 29, 2024
·
10 min read
Press Releases
Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate resistant prostate cancer
May 1, 2025
·
5 min read
Press Releases
Blue Earth Therapeutics Reports Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial
March 13, 2025
·
6 min read
Pharm Country
Blue Earth Diagnostics Highlights Results of Studies Evaluating Impact of Urinary Activity on Image Interpretation and Performance of POSLUMA® (Flotufolastat F 18) and 18F-Flotufolastat PET in Prostate Cancer
Blue Earth Diagnostics announced highlights from clinical studies conducted by its collaborators at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, June 8-11, 2024.
June 10, 2024
·
9 min read
Business
SHINE Technologies Partners with Blue Earth Therapeutics for First Supply of Ilumira from Its New Facility
SHINE Technologies, LLC (SHINE), a pioneer in next-generation fusion-based technology, today announced a new partnership with Blue Earth Therapeutics, a Bracco company and recognized leader in the development of innovative radiopharmaceuticals.
June 6, 2024
·
3 min read
Business
Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting
September 24, 2024
·
7 min read
Drug Development
Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA® (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU
Blue Earth Diagnostics Highlights Clinical Utility of POSLUMA ® (Flotufolastat F 18) PET and Post-scan Changes in Management in Patients with Suspected Recurrence of Prostate Cancer at ASCO GU.
January 25, 2024
·
11 min read
Pharm Country
Blue Earth Therapeutics Announces Participation in Upcoming B. Riley Securities Radiopharma Investor Conference
Blue Earth Therapeutics today announced that it will be presenting at the upcoming B. Riley Securities’ Radiopharma Investor Conference. The event will be held in New York, N.Y., on March 1, 2024.
February 28, 2024
·
3 min read
Business
Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors
Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68 Ga-OncoFAP ( 68 Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors.
December 4, 2023
·
7 min read
Pharm Country
Blue Earth Diagnostics Highlights Presentations on POSLUMA® (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting
Blue Earth Diagnostics Highlights Presentations on POSLUMA ® (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting.
September 27, 2023
·
7 min read
1 of 12,251
Next
